vs
MSC INDUSTRIAL DIRECT CO INC（MSM）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
MSC INDUSTRIAL DIRECT CO INC的季度营收约是Royalty Pharma plc的1.6倍（$965.7M vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 5.4%，领先29.1%），Royalty Pharma plc同比增速更快（4.8% vs 4.0%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs -3.4%）
MSC工业直销公司（MSC）通过旗下主要子公司MSC工业供应公司，是美国规模最大的工业设备分销商之一，可提供超过150万种金属加工及其他工业类产品，广泛服务于工业制造、维修运维等领域的客户需求。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
MSM vs RPRX — 直观对比
营收规模更大
MSM
是对方的1.6倍
$622.0M
营收增速更快
RPRX
高出0.8%
4.0%
净利率更高
RPRX
高出29.1%
5.4%
两年增速更快
RPRX
近两年复合增速
-3.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $965.7M | $622.0M |
| 净利润 | $51.8M | $214.2M |
| 毛利率 | 40.7% | — |
| 营业利润率 | 7.9% | 62.4% |
| 净利率 | 5.4% | 34.4% |
| 营收同比 | 4.0% | 4.8% |
| 净利润同比 | 11.1% | 2.9% |
| 每股收益（稀释后） | $0.93 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MSMRPRX
| Q4 25 | $965.7M | $622.0M | ||
| Q3 25 | $978.2M | $609.3M | ||
| Q2 25 | $971.1M | $578.7M | ||
| Q1 25 | — | $568.2M | ||
| Q4 24 | $928.5M | $593.6M | ||
| Q3 24 | — | $564.7M | ||
| Q2 24 | $979.4M | $537.3M | ||
| Q1 24 | $935.3M | $568.0M |
净利润MSMRPRX
| Q4 25 | $51.8M | $214.2M | ||
| Q3 25 | $56.5M | $288.2M | ||
| Q2 25 | $56.8M | $30.2M | ||
| Q1 25 | — | $238.3M | ||
| Q4 24 | $46.6M | $208.2M | ||
| Q3 24 | — | $544.0M | ||
| Q2 24 | $71.7M | $102.0M | ||
| Q1 24 | $61.8M | $4.8M |
毛利率MSMRPRX
| Q4 25 | 40.7% | — | ||
| Q3 25 | 40.4% | — | ||
| Q2 25 | 41.0% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 40.7% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 40.9% | — | ||
| Q1 24 | 41.5% | — |
营业利润率MSMRPRX
| Q4 25 | 7.9% | 62.4% | ||
| Q3 25 | 8.6% | 70.1% | ||
| Q2 25 | 8.5% | 36.3% | ||
| Q1 25 | — | 94.0% | ||
| Q4 24 | 7.8% | 60.9% | ||
| Q3 24 | — | — | ||
| Q2 24 | 10.9% | 50.2% | ||
| Q1 24 | 9.7% | -13.0% |
净利率MSMRPRX
| Q4 25 | 5.4% | 34.4% | ||
| Q3 25 | 5.8% | 47.3% | ||
| Q2 25 | 5.9% | 5.2% | ||
| Q1 25 | — | 41.9% | ||
| Q4 24 | 5.0% | 35.1% | ||
| Q3 24 | — | 96.3% | ||
| Q2 24 | 7.3% | 19.0% | ||
| Q1 24 | 6.6% | 0.8% |
每股收益（稀释后）MSMRPRX
| Q4 25 | $0.93 | $0.49 | ||
| Q3 25 | $1.02 | $0.67 | ||
| Q2 25 | $1.02 | $0.07 | ||
| Q1 25 | — | $0.55 | ||
| Q4 24 | $0.83 | $0.46 | ||
| Q3 24 | — | $1.21 | ||
| Q2 24 | $1.27 | $0.23 | ||
| Q1 24 | $1.10 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $40.3M | $618.7M |
| 总债务越低越好 | $214.1M | $9.0B |
| 股东权益账面价值 | $1.4B | $9.7B |
| 总资产 | $2.5B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.16× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资MSMRPRX
| Q4 25 | $40.3M | $618.7M | ||
| Q3 25 | $56.2M | $938.9M | ||
| Q2 25 | $71.7M | $631.9M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | $57.3M | $929.0M | ||
| Q3 24 | — | $950.1M | ||
| Q2 24 | $25.9M | $1.8B | ||
| Q1 24 | $22.2M | $843.0M |
总债务MSMRPRX
| Q4 25 | $214.1M | $9.0B | ||
| Q3 25 | $168.8M | $8.9B | ||
| Q2 25 | $285.0M | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | $289.9M | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | $299.8M | $7.6B | ||
| Q1 24 | $294.5M | $6.1B |
股东权益MSMRPRX
| Q4 25 | $1.4B | $9.7B | ||
| Q3 25 | $1.4B | $9.6B | ||
| Q2 25 | $1.4B | $9.5B | ||
| Q1 25 | — | $9.8B | ||
| Q4 24 | $1.4B | $10.3B | ||
| Q3 24 | — | $10.3B | ||
| Q2 24 | $1.4B | $9.8B | ||
| Q1 24 | $1.4B | $9.9B |
总资产MSMRPRX
| Q4 25 | $2.5B | $19.6B | ||
| Q3 25 | $2.5B | $19.3B | ||
| Q2 25 | $2.5B | $18.3B | ||
| Q1 25 | — | $17.6B | ||
| Q4 24 | $2.5B | $18.2B | ||
| Q3 24 | — | $18.0B | ||
| Q2 24 | $2.5B | $17.7B | ||
| Q1 24 | $2.5B | $16.1B |
负债/权益比MSMRPRX
| Q4 25 | 0.16× | 0.92× | ||
| Q3 25 | 0.12× | 0.93× | ||
| Q2 25 | 0.21× | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | 0.21× | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | 0.21× | 0.78× | ||
| Q1 24 | 0.21× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $29.4M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $7.4M | — |
| 自由现金流率自由现金流/营收 | 0.8% | — |
| 资本支出强度资本支出/营收 | 2.3% | — |
| 现金转化率经营现金流/净利润 | 0.57× | 3.86× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流MSMRPRX
| Q4 25 | $29.4M | $827.1M | ||
| Q3 25 | — | $702.6M | ||
| Q2 25 | $151.6M | $364.0M | ||
| Q1 25 | — | $596.1M | ||
| Q4 24 | $101.9M | $742.5M | ||
| Q3 24 | — | $703.6M | ||
| Q2 24 | $143.5M | $658.2M | ||
| Q1 24 | $78.7M | $664.6M |
自由现金流MSMRPRX
| Q4 25 | $7.4M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $100.7M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $81.7M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $114.0M | — | ||
| Q1 24 | $53.4M | — |
自由现金流率MSMRPRX
| Q4 25 | 0.8% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 10.4% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 8.8% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 11.6% | — | ||
| Q1 24 | 5.7% | — |
资本支出强度MSMRPRX
| Q4 25 | 2.3% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 5.2% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 3.0% | — | ||
| Q1 24 | 2.7% | — |
现金转化率MSMRPRX
| Q4 25 | 0.57× | 3.86× | ||
| Q3 25 | — | 2.44× | ||
| Q2 25 | 2.67× | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | 2.18× | 3.57× | ||
| Q3 24 | — | 1.29× | ||
| Q2 24 | 2.00× | 6.45× | ||
| Q1 24 | 1.27× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MSM
暂无分部数据
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
